Cancer clinical trials often face challenges such as long durations, high costs, and ethical concerns regarding patient exposure to potentially ineffective treatments. Adaptive designs can address these issues by allowing for early stopping for efficacy or futility, dose-finding, and patient enrichment strategies. This adaptability can enhance the probability of success and ensure that patients receive the most promising therapies.
